Poster
130
(#130) Real-world use of Xanomeline-Trospium in Schizophrenia: Patient Characteristics and Antipsychotic Treatment Patterns
Psych Congress 2025
Abstract: Introduction: Xanomeline-trospium chloride (X/T) received FDA approval for schizophrenia (SCZ) in September 2024. This is the first real-world study evaluating characteristics and treatment patterns of patients with SCZ initiating X/T in the first five months of its availability in the market.
Methods: This retrospective observational study used administrative claims from Komodo Research Database (1/1/2016-2/28/2025). Adults (≥18 years) with SCZ, ≥2 X/T dispensings (first X/T dispensing defined as the index), and ≥12 months of clinical activity/insurance eligibility before index (baseline) were included. Descriptive analyses of patient demographics, clinical characteristics, antipsychotic (AP) and other psychotropic medication use at baseline were conducted.
Results: Among 556 eligible participants, the mean age was 41.2 years, 60% were male. Most participants were insured by Medicare (44%) or Medicaid (38%). 37% had dyslipidemia at baseline, 33% had an overweight/obesity diagnosis, 25% had type 2 diabetes, and 19% had movement disorder (e.g., dystonia 8%, other extrapyramidal symptoms 8%). During the 12 months prior to X/T initiation, 96% of participants used ≥1 oral AP (e.g., olanzapine 35%, clozapine 24%, aripiprazole 22%), 37% used ≥1 long-acting injectable, over half of participants (52%) used ≥3 distinct APs; 74% patients also used antidepressants, 54% used anxiolytics, and 48% used mood stabilizers.
Conclusions: Participants initiating X/T exhibited high prior utilization of APs and other psychotropic medications, such as antidepressants, anxiolytics, and mood stabilizers. The prevalence of AP-associated comorbidities was also elevated prior to X/T initiation. These preliminary findings provide insight into the profile of adults with SCZ beginning treatment with X/T.
Short Description: This retrospective claims-based study is the first to assess the real-world use of xanomeline-trospium (X/T) in individuals with schizophrenia following its FDA approval. Findings describe patient demographics, comorbidities, and psychotropic medication use before X/T initiation, offering early insights into the characteristics of individuals initiating X/T in the real world.
Name of Sponsoring Organization(s): Bristol Myers Squibb
Methods: This retrospective observational study used administrative claims from Komodo Research Database (1/1/2016-2/28/2025). Adults (≥18 years) with SCZ, ≥2 X/T dispensings (first X/T dispensing defined as the index), and ≥12 months of clinical activity/insurance eligibility before index (baseline) were included. Descriptive analyses of patient demographics, clinical characteristics, antipsychotic (AP) and other psychotropic medication use at baseline were conducted.
Results: Among 556 eligible participants, the mean age was 41.2 years, 60% were male. Most participants were insured by Medicare (44%) or Medicaid (38%). 37% had dyslipidemia at baseline, 33% had an overweight/obesity diagnosis, 25% had type 2 diabetes, and 19% had movement disorder (e.g., dystonia 8%, other extrapyramidal symptoms 8%). During the 12 months prior to X/T initiation, 96% of participants used ≥1 oral AP (e.g., olanzapine 35%, clozapine 24%, aripiprazole 22%), 37% used ≥1 long-acting injectable, over half of participants (52%) used ≥3 distinct APs; 74% patients also used antidepressants, 54% used anxiolytics, and 48% used mood stabilizers.
Conclusions: Participants initiating X/T exhibited high prior utilization of APs and other psychotropic medications, such as antidepressants, anxiolytics, and mood stabilizers. The prevalence of AP-associated comorbidities was also elevated prior to X/T initiation. These preliminary findings provide insight into the profile of adults with SCZ beginning treatment with X/T.
Short Description: This retrospective claims-based study is the first to assess the real-world use of xanomeline-trospium (X/T) in individuals with schizophrenia following its FDA approval. Findings describe patient demographics, comorbidities, and psychotropic medication use before X/T initiation, offering early insights into the characteristics of individuals initiating X/T in the real world.
Name of Sponsoring Organization(s): Bristol Myers Squibb
